Prolonged Localization of a Monoclonal Antibody in Colon Tumors
Author Information
Author(s): P.J. Harwood, R.B. Pedley, J. Boden, G. Rawlins, C.R. Pentycross, G.T. Rogers, K.D. Bagshawe
Primary Institution: Cancer Research Campaign Laboratories, Charing Cross Hospital
Hypothesis
Can a monoclonal antibody against CEA effectively localize in human colon tumor xenografts?
Conclusion
The study suggests that the monoclonal antibody 1H12 can remain in tumors for an extended period, enhancing its potential for therapeutic use.
Supporting Evidence
- The antibody 1H12 showed a significant accumulation in tumors compared to normal tissues.
- 1H12 remained in the tumor at maximal levels for at least 12 days after injection.
- The tumor:blood ratio for 1H12 increased from 0.04:1 at 1 hour to over 3:1 at 12 days.
Takeaway
Researchers found that a special antibody can stay in colon tumors for a long time, which might help in treating cancer better.
Methodology
The study used a paired distribution method to evaluate the localization of the monoclonal antibody 1H12 in a xenograft model with tissue counting at various time points.
Limitations
The study is preliminary and does not explore the effects of escalating and sequential doses in therapy.
Participant Demographics
Nude mice bearing the MAWI xenograft derived from a human colon adenocarcinoma.
Want to read the original?
Access the complete publication on the publisher's website